Qingjun Li

Qingjun Li

Auto-generated profile, based on publicly available information

Qingjun Li

Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LHLu Han
Lu Han
KLKang Li
Kang Li
CJChaozhi Jin
Chaozhi Jin
JWJian Wang
Jian Wang
QLQingjun Li
Qingjun Li
SWShengqi Wang
Shengqi Wang
As a predominant cause of human hand, foot, and mouth disease, enterovirus 71 (EV71) infection may lead to serious diseases and result in severe consequences that threaten public health and cause widespread panic. Although the systematic identification of physical interactions between viral proteins and host proteins provides initial information for the recognition of the cellular mechanism involved in viral infection and the development of new therapies, EV71-host protein interactions have not been explored. Here, we identified interactions between EV71 proteins and host cellular proteins and confirmed the functional relationships of EV71-interacting proteins (EIPs) with virus proliferation and infection by integrating a human protein interaction network and by functional annotation. We found that most EIPs had known interactions with other viruses. We also predicted ATP6V0C as a broad-spectrum essential host factor and validated its essentiality for EV71 infection in vitro. EIPs and their interacting proteins were more likely to be targets of anti-inflammatory and neurological drugs, indicating their potential to serve as host-oriented antiviral targets. Thus, we used a connectivity map to find drugs that inhibited EIP expression. We predicted tanespimycin as a candidate and demonstrated its antiviral efficiency in vitro. These findings provide the first systematic identification of EV71-host protein interactions, an analysis of EIP protein characteristics and a demonstration of their value in developing host-oriented antiviral therapies.

1 June 2021 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
YZYanzhao Zhou
Yanzhao Zhou
YYYi Yang
Yi Yang
BZBingyan Zhou
Bingyan Zhou
ZWZhengzheng Wang
Zhengzheng Wang
RZRuili Zhu
Ruili Zhu
ZJZhou Jinxue
Zhou Jinxue
As an emerging minimally invasive treatment method, percutaneous ablation is more and more widely used in the treatment of liver tumors. It has been recommended by guidelines for diagnosis and treatment of hepatocellular carcinoma (HCC) as a curative treatment alongside surgical resection and liver transplantation. In recent years, with the continuous advancement and innovation of percutaneous ablation technologies, their clinical efficacy and safety have been significantly improved, which has led to the expanded application of percutaneous ablation in the treatment of HCC—more and more patients who were previously considered unsuitable for ablation therapies are now being treated with percutaneous ablation. Obviously, percutaneous ablation can reduce the risk of treatment changes from curative strategies to palliative strategies. Based on clinical practice experience, this review enumerates the advantages and disadvantages of different ablative modalities and summarizes the existing combinations of ablation techniques, thus will help clinicians choose the most appropriate ablative modality for each patient and will provide scientific guidance for improving prognosis and making evidence-based treatment decisions. In addition, we point out the challenges and future prospects of the ablation therapies, thereby providing direction for future research.

10 May 2011 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
JCJinsong Cai
Jinsong Cai
YHYuyan Hu
Yuyan Hu
WLWenbin Li
Wenbin Li
LLLi Li
Li Li
SLShuqin Li
Shuqin Li
QLQingjun Li
Qingjun Li

1 September 2023 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
JOJingzhong Ouyang
Jingzhong Ouyang
ZWZhengzheng Wang
Zhengzheng Wang
KYKun Yuan
Kun Yuan
YYYi Yang
Yi Yang
YZYanzhao Zhou
Yanzhao Zhou
ZJZhou Jinxue
Zhou Jinxue
Purpose: To evaluate the efficacy and safety of lenvatinib plus programmed death-1 (PD-1) antibody as postoperative adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risks of recurrence. Patients and Methods: A series of 137 patients with HCC at high risks of recurrence who underwent hepatectomy at our hospital between October 2019 and January 2022 were retrospectively analyzed. Recurrence-free survival (RFS), overall survival (OS), and treatment-related adverse events (TRAEs) were assessed. Landmark analysis was used to compare short- and long-term RFS. Univariable and multivariable analyses were used to identify prognostic factors, and subgroup analyses were performed according to high risks of recurrence. Results: A total of 85 patients underwent hepatectomy alone and 52 patients received postoperative adjuvant therapy. Compared with the hepatectomy group (HG), RFS was significantly improved in the adjuvant therapy group (ATG) (P < 0.001), but OS was not (P = 0.098). Landmark analysis revealed that RFS within 6 months of the HG was significantly different from that of the ATG (P < 0.001) but not after 6 months (P = 0.486). Multivariable analysis showed that without adjuvant therapy, high Child-Pugh classification, high alpha-fetoprotein levels, microvascular invasion, and satellite lesions were independent risk factors for recurrence within 6 months after hepatectomy. Subgroup analysis revealed that patients with MVI significantly benefited from adjuvant therapy in RFS. But for OS, adjuvant therapy was only significantly effective in patients with single tumor. The most common treatment-related adverse events during adjuvant therapy were hypertension (36.5%), rash or itching (28.8%), diarrhea (23.1%), and fatigue (21.2%). Conclusion: Postoperative adjuvant lenvatinib plus PD-1 antibody significantly improved RFS in patients with HCC at high risks of recurrence with acceptable safeties.

1 August 2024 in HepatoBiliary Surgery and Nutrition
Verified
Journal Article
Open access
PDF file
JOJingzhong Ouyang
Jingzhong Ouyang
YYYi Yang
Yi Yang
YZYanzhao Zhou
Yanzhao Zhou
XCXu Chang
Xu Chang
ZWZhengzheng Wang
Zhengzheng Wang
HZHong Zhao
Hong Zhao
Original Article Adjuvant camrelizumab plus apatinib in resected hepatocellular carcinoma with microvascular invasion: a multi-center real world study Jingzhong Ouyang, Yi Yang, Yanzhao Zhou, Xu Chang, Zhengzheng Wang, Qingjun Li, Yu Tang, Jianqiang Cai, Jinxue Zhou, Zhen Huang, Hong Zhao

1 June 2024 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
YZYanzhao Zhou
Yanzhao Zhou
JOJingzhong Ouyang
Jingzhong Ouyang
HYHongcai Yang
Hongcai Yang
ZWZhengzheng Wang
Zhengzheng Wang
YYYi Yang
Yi Yang
QLQiang Li
Qiang Li
Purpose: The impact of visceral adiposity on overall survival (OS) in hepatocellular carcinoma (HCC) receiving immunotherapy was unclear. We aimed to determine how visceral adiposity affected OS and explore the interrelationships between visceral adiposity, body mass index (BMI), and other body compositions. Patients and Methods: Data from three centers were retrospectively analyzed. Skeletal muscle index (SMI), skeletal muscle density (SMD), visceral adipose tissue index (VATI), and subcutaneous adipose tissue index (SATI) were used to define each body composition. The BMI subgroups included the underweight, the normal weight, and the obesity. The Log rank test compared survival curves calculated by the Kaplan-Meier method. The relationships between body compositions and BMI with OS were examined using Cox proportional risk regression models. Results: A total of 305 patients who met the criteria were included. Patients with low VATI had significantly worse OS (P = 0.001). The protections of VATI (P = 0.011) on OS were independent of covariates. However, after additional adjustment of SMI, the effect of VATI on OS disappeared (P = 0.146), but the effect of SMD on OS did not (P = 0.021). BMI has a significant U-shaped relationship with OS, and the effect of BMI on OS equally disappeared after additional adjustment by SMI. Conclusion: This study first demonstrated that high VATI and mid-level BMI were protective for the survival of patients with HCC receiving immunotherapy. Skeletal muscle status (including SMI and SMD) may be the better predictor for outcomes of patients with HCC receiving immunotherapy.